Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genome-wide analysis of Schistosoma mansoni reveals limited population structure and possible praziquantel drug selection pressure within Ugandan hot-spot communities.
Vianney TJ, Berger DJ, Doyle SR, Sankaranarayanan G, Serubanja J, Nakawungu PK, Besigye F, Sanya RE, Holroyd N, Allan F, Webb EL, Elliott AM, Berriman M, Cotton JA. Vianney TJ, et al. Among authors: serubanja j. PLoS Negl Trop Dis. 2022 Aug 18;16(8):e0010188. doi: 10.1371/journal.pntd.0010188. eCollection 2022 Aug. PLoS Negl Trop Dis. 2022. PMID: 35981002 Free PMC article.
Does Intensive Treatment Select for Praziquantel Resistance in High-Transmission Settings? Parasitological Trends and Treatment Efficacy Within a Cluster-Randomized Trial.
Tushabe JV, Lubyayi L, Sserubanja J, Kabuubi P, Abayo E, Kiwanuka S, Nassuuna J, Kaweesa J, Corstjens P, van Dam G, Sanya RE, Ssenyonga W, Tukahebwa EM, Kabatereine NB, Elliott AM, Webb EL; LaVIISWA trial team. Tushabe JV, et al. Open Forum Infect Dis. 2020 Mar 12;7(4):ofaa091. doi: 10.1093/ofid/ofaa091. eCollection 2020 Apr. Open Forum Infect Dis. 2020. PMID: 32296727 Free PMC article.
Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Nkurunungi G, Zirimenya L, Nassuuna J, Natukunda A, Kabuubi PN, Niwagaba E, Oduru G, Kabami G, Amongin R, Mutebe A, Namutebi M, Zziwa C, Amongi S, Ninsiima C, Onen C, Akello F, Sewankambo M, Kiwanuka S, Kizindo R, Kaweesa J, Cose S, Webb E, Elliott AM; POPVAC trial team; POPVAC trial team principal investigator. Nkurunungi G, et al. BMJ Open. 2021 Feb 16;11(2):e040426. doi: 10.1136/bmjopen-2020-040426. BMJ Open. 2021. PMID: 33593768 Free PMC article.
Maternal Latent Mycobacterium tuberculosis Does Not Affect the Infant Immune Response Following BCG at Birth: An Observational Longitudinal Study in Uganda.
Lubyayi L, Mawa PA, Nabakooza G, Nakibuule M, Tushabe JV, Serubanja J, Aibo D, Akurut H, Tumusiime J, Hasso-Agopsowicz M, Kaleebu P, Levin J, Dockrell HM, Smith S, Webb EL, Elliott AM, Cose S. Lubyayi L, et al. Among authors: serubanja j. Front Immunol. 2020 May 14;11:929. doi: 10.3389/fimmu.2020.00929. eCollection 2020. Front Immunol. 2020. PMID: 32477371 Free PMC article.
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Natukunda A, Nkurunungi G, Zirimenya L, Nassuuna J, Oduru G, Amongin R, Kabuubi PN, Mutebe A, Onen C, Amongi S, Nakazibwe E, Akello F, Kiwanuka S, Kiwudhu F, Sewankambo M, Nsubuga D, Kizindo R, Staedke SG, Cose S, Webb E, Elliott AM; POPVAC trial team. Natukunda A, et al. BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427. BMJ Open. 2021. PMID: 33593769 Free PMC article.
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Zirimenya L, Nkurunungi G, Nassuuna J, Natukunda A, Mutebe A, Oduru G, Kabami G, Akurut H, Onen C, Namutebi M, Serubanja J, Nakazibwe E, Akello F, Tumusiime J, Sewankambo M, Kiwanuka S, Kiwudhu F, Kizindo R, Kizza M, Wajja A, Cose S, Muwanga M, Webb E, Elliott AM; POPVAC trial team. Zirimenya L, et al. Among authors: serubanja j. BMJ Open. 2021 Feb 16;11(2):e040430. doi: 10.1136/bmjopen-2020-040430. BMJ Open. 2021. PMID: 33593770 Free PMC article.
Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials.
Natukunda A, Nkurunungi G, Zirimenya L, Nassuuna J, Zziwa C, Ninsiima C, Tumusiime J, Nyanzi R, Namutebi M, Kiwudhu F, van Dam GJ, Corstjens PLAM, Kizindo R, Nkangi R, Kabagenyi J, Nassanga B, Cose S, Wajja A, Kaleebu P, Elliott AM, Webb EL; POPVAC trial team. Natukunda A, et al. Lancet Glob Health. 2024 Nov;12(11):e1860-e1870. doi: 10.1016/S2214-109X(24)00340-1. Lancet Glob Health. 2024. PMID: 39424574 Free PMC article. Clinical Trial.
The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents (POPVAC C): an open-label, randomised controlled trial.
Nassuuna J, Zirimenya L, Nkurunungi G, Natukunda A, Zziwa C, Ninsiima C, Apule B, Onen C, Amongi S, Serubanja J, Tumwesige P, Nsubuga D, Amongin R, van Dam GJ, Corstjens PLAM, Kayiwa J, Kabagenyi J, Cose S, Wajja A, Kaleebu P, Webb EL, Elliott AM; POPVAC trial team. Nassuuna J, et al. Among authors: serubanja j. Lancet Glob Health. 2024 Nov;12(11):e1849-e1859. doi: 10.1016/S2214-109X(24)00282-1. Lancet Glob Health. 2024. PMID: 39424573 Free PMC article. Clinical Trial.
The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda (POPVAC B): a double-blind, randomised controlled trial.
Zirimenya L, Natukunda A, Nassuuna J, Nkurunungi G, Zziwa C, Ninsiima C, Kukundakwe C, Nankabirwa CM, Katushabe C, Namusobya LK, Oduru G, Kabami G, Kabali J, Kayiwa J, Kabagenyi J, van Dam GJ, Corstjens PLAM, Cose S, Wajja A, Staedke SG, Kaleebu P, Elliott AM, Webb EL; POPVAC trial team. Zirimenya L, et al. Lancet Glob Health. 2024 Nov;12(11):e1838-e1848. doi: 10.1016/S2214-109X(24)00281-X. Lancet Glob Health. 2024. PMID: 39424572 Free PMC article. Clinical Trial.
The effect of intensive praziquantel administration on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands (POPVAC A): an open-label, randomised controlled trial.
Nkurunungi G, Nassuuna J, Natukunda A, Zirimenya L, Walusimbi B, Zziwa C, Ninsiima C, Kabagenyi J, Kabuubi PN, van Dam GJ, Corstjens PLAM, Kayiwa J, Kizza M, Mutebe A, Nakazibwe E, Akello FA, Sewankambo M, Kiwanuka S, Cose S, Wajja A, Kaleebu P, Webb EL, Elliott AM; POPVAC trial team. Nkurunungi G, et al. Lancet Glob Health. 2024 Nov;12(11):e1826-e1837. doi: 10.1016/S2214-109X(24)00280-8. Lancet Glob Health. 2024. PMID: 39424571 Free PMC article. Clinical Trial.
12 results